Key Developments: Grifols SA (GRLS.MC)

GRLS.MC on Madrid SE C.A.T.S.

36.88EUR
28 Aug 2015
Change (% chg)

€0.09 (+0.23%)
Prev Close
€36.80
Open
€36.94
Day's High
€37.06
Day's Low
€36.38
Volume
456,583
Avg. Vol
674,965
52-wk High
€42.90
52-wk Low
€27.91

Search Stocks

Latest Key Developments (Source: Significant Developments)

Grifols SA and Ortho Clinical Diagnostics sign a $700 mln deal extention with Abbott
Monday, 20 Jul 2015 02:29am EDT 

Grifols SA:Signs with Ortho Clinical Diagnostics a $700 mln deal extention with Abbott for antigen production.Deal covers production of antigens already produced and five new ones in a production plant that is being constructed in Emeryville, California.New contract extends until 2026.  Full Article

Grifols SA declares FY 2014 dividend
Friday, 29 May 2015 08:15am EDT 

Grifols SA:Declares FY 2014 dividend of 100,849,671 euros total, payable on June 8.Declares obligatory preferred dividend of 0.01 euros per share, payable June 8.  Full Article

Grifols SA to make a major equity investment in Alkahest
Wednesday, 4 Mar 2015 02:29am EST 

Grifols SA:Says the company and Alkahest, a privately held biopharmaceutical company, announced that they have signed definitive agreements whereby Grifols will make a major equity investment in Alkahest.Companies will work together to develop novel plasma-based products for the treatment of cognitive decline in aging and disorders of the central nervous system (CNS), including Alzheimer's.Grifols will make a $37.5 million equity investment in the form of a cash payment in exchange for 45 pct of Alkahest's shares following the closing of the transaction.In addition Grifols will provide a further payment of $12.5 million and fund the development of plasma-based products, which may be commercialized by Grifols throughout the world.Alkahest will receive milestone payments and royalties on sales of such products by Grifols.Grifols will have two seats on Alkahest's Board of Directors and will collaborate with Alkahest researchers through the creation of a Scientific Joint Steering Committee.  Full Article

Grifols gets FDA approval for purification plant in Los Angeles, US
Wednesday, 31 Dec 2014 02:42am EST 

Grifols SA:Gets Food and Drug Administration (FDA) approval for new Grifols Biologicals Inc. purification plant in Los Angeles.New plant to manufacture Immune Globulin Injection (Gamunex).With FDA authorization Grifols increases its manufacturing capacity of Gamunex to maximum of 17 million grams annually in this plant.Investment value 53 million euros.New investment to generate 100 jobs and to begin operations in 2015.  Full Article

Grifols declares FY 2014 interim dividend
Tuesday, 21 Oct 2014 05:26am EDT 

Grifols SA:Declares interim dividend for 2014 of 0.25 euro per share.Dividend to be paid in the first week of Dec. 2014.  Full Article

Grifols buys 50 pct of Kiro Robotics for 21 mln euros; signs JV agreement with co's shareholders
Thursday, 18 Sep 2014 08:00pm EDT 

Grifols SA:Says it has bought 50 percent of Kiro Robotics by subscribing equity offering for 21 million euros in cash.Says it has signed Joint Venture agreement with company‚Äôs other shareholders: Mondragon Innovacion, MondragonAssembly, Agrupacion de Fundicion y Utillaje, all part of MONDRAGON Corporation.Deal regulates equity offering subscribed by Grifols and representation on governing bodies and management of Kiro Robotics.Says JV agreement establishes minimum commitment or lock-up period of four years from date of signature.  Full Article

Grifols SA opens facility in Clayton, NC to help advance treatment of rare and life-threatening diseases
Tuesday, 17 Jun 2014 09:00am EDT 

Grifols SA:Opening of new North Fractionation Facility (NFF) in Clayton, NC, where production capacity of plasma will almost double to about 6 mln liters annually.Grifols' products are used to treat rare, chronic diseases such as a neurological disorder, immune deficiencies, hemophilia and genetic emphysema.  Full Article

Grifols declares FY 2013 dividend
Friday, 30 May 2014 07:49am EDT 

Grifols SA:Declares dividend for 2013 of 68,755,491 euros.Dividend to be paid on June 5.Declares preferential dividend of 0.01 euro per each class B share.Dividend to be paid on June 5.  Full Article

Grifols opens new plasma fractionation plant in Spain
Friday, 4 Apr 2014 06:33am EDT 

Grifols SA:Opens new plasma fractionation plant at Parets del Valles (Barcelona, Spain).Plant with capacity to fractionate 2.1 million liters of plasma per year.New facilities double company plasma fractionation capacity in Spain, taking it to 4.2 million liters/year.Allocates over 20 million euros to these manufacturing facilities, which will gradually generate almost 100 jobs.Plant occupies 4,500 m2, divided over three floors.New facilities designed by Grifols Engineering SA.  Full Article

Sociedad Cruz Roja Japonesa to use Grifols Procleix
Monday, 31 Mar 2014 02:28am EDT 

Grifols SA:Says on March 28 la Sociedad Cruz Roja Japonesa signed contract to use Grifols technique Procleix for analysis of blood.Seven-year contract worth about 274,000,000 euros.Contracts formalized through Novartis Pharma KK.  Full Article

BRIEF-Spain's Grifols H1 net profit up 16 pct, beats forecast

* Says H1 net profit up 16.3 pct to 261.5 million euros ($286.4 million), above 258 million euros forecast in Reuters poll

Search Stocks